Navigation Links
Hard To Treat Diseases (HTDS.PK) Completes India Order

SHENZHEN, China, July 10 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) - announced today that the second batch of Hepatitis A Vaccine of 2009 was delivered to India, by the company.

This is the second completed batch exported to India this year by the company. The first batch was delivered to India in March.

In summary, many people are recommended to receive Hepatitis A vaccine, including people at increased risk for exposure to HAV infection and people who are more likely to get seriously ill if infected with HAV. According to CDC recommendations, people who should be vaccinated include:

    -   All children at age 1 year (12-23 months)
    -   People age 12 months or older who are traveling to or working in an
        area of the world except the United States, Canada, Western Europe,
        Japan, New Zealand, and Australia
    -   Men who have sex with men
    -   Users of illegal drugs, both oral and injecting
    -   People who have blood clotting disorders
    -   People who work with HAV-infected primates or with HAV in a research
        laboratory setting (no other groups have been shown to be at
        increased risk for HAV infection because of occupational exposure)
    -   People with chronic liver disease
    -   Any person who wishes to be immune to Hepatitis A

More about of Hepatitis A Vaccine can be found on this World Health Organization link

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard To Treat Diseases Inc that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. Hard To Treat Diseases Inc cautions you that any forward-looking information provided by or on behalf of Hard To Treat Diseases Inc is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard To Treat Diseases Inc's actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard To Treat Diseases Inc's control. In addition to those discussed in Hard To Treat Diseases Inc's press releases, public filings, and statements by Hard To Treat Diseases Inc's management, including, but not limited to, Hard To Treat Diseases Inc's estimate of the sufficiency of its existing capital resources, Hard To Treat Diseases Inc's ability to raise additional capital to fund future operations, Hard To Treat Diseases Inc's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard To Treat Diseases Inc's capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard To Treat Diseases Inc does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact; For any corporate matters, please contact,

SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hard To Treat Diseases (HTDS.PK) Reasserting Multi Million Dollar IP Ownership Rights
2. Anti-angiogenesis treatment improves hearing in some NF2 patients
3. Drug Shows Promise in Nervous-System Tumor Treatment
4. Advanced Heart Procedure Treats Growing Problem
5. 'Comparative Effectiveness' Research Addresses Options for Treating Prostate Cancer
6. Evidence-based information about complementary and alternative medicine treatments now available
7. Researchers identify potential patient safety risks among methadone maintenance treatment patients
8. Global Fund Increases AIDS, Tuberculosis and Malaria Prevention and Treatment Measures by 30-50% Over One Year
9. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
10. National Survey: Americans Fear Paying for Cancer Treatment As Much As Dying of the Disease
11. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
Post Your Comments:
(Date:11/29/2015)... ... ... Key Housing, a top-rated corporate housing service for the San Jose and ... In showcasing this featured apartment community in San Jose, Key Housing is helping those ... find housing suitable to their needs by showcasing quality housing. , “San Jose many ...
(Date:11/28/2015)... , ... November 28, 2015 , ... Beginning November 30th at 6:00 a.m. EST until ... most savings. , With possible savings of up to 20% off orders $80 or more ... of the website every few hours. , As a competitive e-commerce website for skin care ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... and the University of British Columbia suggested that laws requiring bicyclists to wear helmets ... that part of the reason for the controversial conclusion is that, while helmets have ...
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... to be a safe and convenient way to dispense prescription medications at home, ... safe and effective way to monitor and dispense prescription medications. In doing so, ...
(Date:11/27/2015)... ... 27, 2015 , ... ProSidebar: Fashion is a set of 30 ... ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX production. ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease of ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... November 26, 2015 ... "Self Administration of High Viscosity Drugs" report ... has announced the addition of the "Self ... their offering. --> Research and Markets ... the "Self Administration of High Viscosity Drugs" ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Marker Testing Market: Supplier Shares, ... their offering.  --> ... the  "2016 Future Horizons and Growth ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: